# EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid Arthritis

> **NCT07349420** · PHASE1,PHASE2 · COMPLETED · sponsor: **S.LAB (SOLOWAYS)** · enrollment: 48 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** EF-M2

## Key facts

- **NCT ID:** NCT07349420
- **Lead sponsor:** S.LAB (SOLOWAYS)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-03
- **Primary completion:** 2025-10-05
- **Final completion:** 2025-12-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349420, "EF-M2 (Immutalon) Multiple Ascending Dose Study in Moderate-to-Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07349420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*